52833-94-0

Usage

Chemical Properties

Light yellow powder

InChI:InChI=1/C6H5BrN2O2/c7-3-1-4(6(10)11)5(8)9-2-3/h1-2H,(H2,8,9)(H,10,11)

Upstream product

• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 50735-34-7 methyl 2-amino-5-bromopyridine-3-carboxylate 

Downstream Products

• 1092580-97-6 2-amino-5-bromo-N,N-dimethylnicotinamide 
• 58483-98-0 2-amino-5-bromo-nicotinamide 
• 335031-01-1 2-amino-5-bromo-3-(hydroxymethyl)pyridine 
• 903129-78-2 6-bromoimidazo[1,2-a]pyridine-8-carboxylic acid 

Relevant academic research and scientific papers

SYNTHESIS, CRYSTAL STRUCTURE AND DFT STUDY OF NOVEL (2S,2′S,6R,6′R)-4,4′-(6-BROMOPYRIDO[2,3-d]PYRIMIDINE-2,4-DIYL)BIS(2,6-DIMETHYLMORPHOLINE)

Abstract: (2S,2′S,6R,6′R)-4,4′-(6-Bromopyrido[2,3-d]pyrimidine-2,4-diyl)bis(2,6-dimethylmorpholine) is a novel organic intermediate having pyrido[2,3-d]pyrimidine. It is synthesized by four steps and confirmed by 1H and 13C NMR and FTIR spectroscopy and MS. Meanwhile, the single crystal of the title compound is subjected to the crystallographic analysis and the conformation determination. Moreover, density functional theory (DFT) is used to calculate the optimized structures of the molecule which are compared with the X-ray measurement. The result of the molecular structure optimized by DFT is consistent with the crystal structure determined by single crystal X-ray diffraction. Finally, in order to further investigate some physical properties of the title compound by the B3LYP/6-311G(2d,p) method, the molecular electrostatic potential and frontier molecular orbitals are calculated. The calculated and experimental data show that the title compound has good chemical stability and nucleophilic reactivity. Hirshfeld surface analyses can explain the atom pair contacts of the crystal and the quantitative analysis of intermolecular interactions is performed. [Figure not available: see fulltext.]

Compound constituting a hole transfer layer and an electron transfer layer of an organic light emitting diode or a method for producing the same

The present invention relates to a compound constituting a hole transport layer and an electron transport layer of an organic light emitting diode, or a method for manufacturing the same. According to the present invention, it is possible to provide a plurality of compounds having excellent yields and excellent purity constituting the hole transport layer and the electron transport layer. An object of the present invention is to provide the compound constituting the hole transport layer and the electron transport layer of the organic light emitting diode, or the method for manufacturing the same.(AA) HPLC analysis result of a final productCOPYRIGHT KIPO 2020

Regioselective palladium-catalyzed Suzuki–Miyaura coupling reaction of 2,4,6-trihalogenopyrido[2,3-d]pyrimidines

An effective, regioselective, and novel strategy to the access of 2,4,6-trisubstituted pyrido[2,3-d]pyrimidines is developed from the corresponding 2,4,6-trihalogenopyrido[2,3-d]pyrimidine through a Suzuki–Miyaura coupling reaction involving a novel regioselective halogen discrimination.

3 - (1, 3, 4 - Oxadiazolyl) - 5 - phenoxy - pyridine derivative and its preparation method and application

The invention discloses a new compound 3-(1, 3, 4-oxadiazol)-5-phenoxy-pyridine derivative, a preparation method and application thereof. The structural formula of the compound is shown as formula I, wherein R1 is H, or R1 can be one or more of the following monosubstituted or polysubstituted groups on benzene ring: fluorine, chlorine, bromine, methyl, methoxy, hydroxyl, nitro, amino, acetylamino, trifluoromethyl and cyano; R2 can be pyridyl, furyl, thienyl, and acylamino; under the circumstance of R3=H, R4=NH2 and R3=NH2, R4=H or R3=R4=H; X is O or S or NH or NCH3. The compound provided by the invention has good antitumor activity, and can be used as a therapeutic agent for tumor treatment in the field of anti-tumor drug preparation. (formula I).

Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A

Dual-specificity tyrosine phosphorylation-related kinase 1A (DYRK1A) is a dual-specificity protein kinase that catalyses phosphorylation and autophosphorylation. Higher DYRK1A expression correlates with cancer, in particular glioblastoma present within the brain. We report here the synthesis and biological evaluation of new heterocyclic diphenolic derivatives designed as novel DYRK1A inhibitors. The generation of these heterocycles such as benzimidazole, imidazole, naphthyridine, pyrazole-pyridines, bipyridine, and triazolopyrazines was made based on the structural modification of the lead DANDY and tested for their ability to inhibit DYRK1A. None of these derivatives showed significant DYRK1A inhibition but provide valuable knowledge around the importance of the 7-azaindole moiety. These data will be of use for developing further structure-activity relationship studies to improve the selective inhibition of DYRK1A.

NEW COMPOUNDS AND ORGANIC ELECTRONIC DEVICE CONTAINING THE SAME

The present invention relates to a novel compound and to an organic electronic device containing the same. According to the present invention, a compound having an extended conjugate length and excellent planarity is provided, and the organic electronic device containing the same, with the structural characteristics, can exhibit remarkable power-conversion efficiency by simultaneously realizing the improvement of the short circuit current density, the charging rate and the open-circuit voltage value.COPYRIGHT KIPO 2018

HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS

The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.

6-pyrromonazole substituted quinazoline compound, and derivative, synthetic method and application thereof

The invention discloses a compound as shown in the formula (I), (II) or (III), or salt of the compound acceptable in pharmacy, aquo-complex, a solvate, a polymorphic substance, a tautomer or a prodrug; a synthetic method of the formula (I) comprises the f

The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors

Leucine-rich repeat kinase 2 (LRRK2) has attracted considerable interest as a therapeutic target for the treatment of Parkinson's disease. Compounds derived from a 2-aminopyridine screening hit were optimised using a LRRK2 homology model based on mixed li

Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor

Three series of novel quinazoline and pyrido[2,3-d]pyrimidine derivatives were designed, synthesized and evaluated for their ability to inhibit EGFR tyrosine kinase and a panel of five human cancer cell lines (MCF-7, A549, BT-474, SK-BR-3, and MDA-MB-231)